Literature DB >> 16866652

Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation.

P J Roberts-Thomson1, J G Walker, T Y-T Lu, A Esterman, P Hakendorf, M D Smith, M J Ahern.   

Abstract

The aim of this study was to determine the incidence, prevalence, survival and selective demographic characteristics of scleroderma occurring in South Australia over the 10-year period 1993-2002. Analysis of the database of the South Australian Scleroderma Register: a population-based register established in 1993. Patients with scleroderma resident in South Australia (n = 353 at 2002) were ascertained from multiple sources and clinical and demographic data were obtained from mailed questionnaire and from review of computerized hospital databases, case notes or referring letters. Time-space cluster analysis was carried out according to the Knox method. Control data were obtained from the Australian Bureau of Statistics census. The mean prevalence was 21.4 per 10(5) (95% confidence interval 20.2-22.6) and the mean cumulative incidence of 1.5 per 10(5) (95% confidence interval 1.32-1.73) with no significant change in incidence over the study period (P = 0.13). Cumulative survival improved over the study period, with patients with diffuse disease having significantly reduced survival (as compared with limited disease, P < 0.001). The proportion with diffuse disease ( approximately 22%) remained steady. There was a small but significant predisposition in patients with a continental European birthplace (P < 0.001). A family history of scleroderma was noted in 1.6% with lambda1 (familial risk) of 14.3 (95% confidence interval 5.9-34.5). However, a family history of systemic autoimmunity (especially rheumatoid arthritis) was more common (6%). No socioeconomic stratification, temporal clustering nor spatio-temporal clustering was observed either at time of initial symptom or at 10 years before disease onset. Scleroderma occurs relatively infrequently in South Australia with no significant change in incidence observed over the 10-year study period. However, cumulative survival has improved. Identified risk factors include family history of scleroderma (risk approximately 14-fold), female sex (risk approximately 5-fold) and European birthplace (risk approximately 2.5-fold); however, the majority of the disease variance appears unexplained. A stochastic explanation based on genetic instability is favoured to explain this paradox.

Entities:  

Mesh:

Year:  2006        PMID: 16866652     DOI: 10.1111/j.1445-5994.2006.01125.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  9 in total

Review 1.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Prevalence of Skin and Skin-Related Diseases in the Rochester Epidemiology Project and a Comparison with Other Published Prevalence Studies.

Authors:  Louise K Andersen; Mark D P Davis
Journal:  Dermatology       Date:  2016-03-25       Impact factor: 5.366

3.  Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period.

Authors:  Paolo Airò; Francesca Regola; Maria-Grazia Lazzaroni; Angela Tincani; Flora Inverardi; Maria Giulia Fenini; Francesco Ferrè; Roberto Furloni; Mirko Scarsi
Journal:  J Scleroderma Relat Disord       Date:  2019-01-13

Review 4.  A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Silvia Piantoni; Fabrizio Angeli; Stefania Bertocchi; Franco Franceschini; Paolo Airò
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-07       Impact factor: 10.817

5.  Mortality trends in systemic sclerosis in France and USA, 1980-1998: an age-period-cohort analysis.

Authors:  Solen Kernéis; Pierre-Yves Boëlle; Rebecca Freeman Grais; Gérard Pavillon; Eric Jougla; Antoine Flahault; Lone Simonsen; Thomas Hanslik
Journal:  Eur J Epidemiol       Date:  2009-11-13       Impact factor: 8.082

6.  Foot health needs in people with systemic sclerosis: an audit of foot health care provision.

Authors:  Begonya Alcacer-Pitarch; Heidi J Siddle; Maya H Buch; Paul Emery; Farina Hashmi; Anthony C Redmond
Journal:  Clin Rheumatol       Date:  2011-06-10       Impact factor: 2.980

7.  Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study.

Authors:  Kathleen Morrisroe; Wendy Stevens; Joanne Sahhar; Gene-Siew Ngian; Candice Rabusa; Nava Ferdowsi; Catherine Hill; Susanna Proudman; Mandana Nikpour
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Risk factors for the development of systemic sclerosis: a systematic review of the literature.

Authors:  Samuel Abbot; David Bossingham; Susanna Proudman; Caroline de Costa; Albert Ho-Huynh
Journal:  Rheumatol Adv Pract       Date:  2018-10-11

9.  The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink.

Authors:  Jeremy G Royle; Peter C Lanyon; Matthew J Grainge; Abhishek Abhishek; Fiona A Pearce
Journal:  Clin Rheumatol       Date:  2018-06-30       Impact factor: 2.980

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.